News
Zacks.com on MSN2mon
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLAWith the FDA granting a priority review to the BLA, a decision from the regulatory body is expected on July 22, 2025. Shares ...
Replimune Group, Inc.’s REPL share price has dipped by 9.10%, which has investors questioning if this is right time to buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback